Enfuvirtide Acetate (T-20)
Alias:Fuzeon
Sequenz:CH3CO-Tyr-Thr-Ser-Leu-Ile-His-Ser-Leu-Ile-Glu-Glu-Ser-Gln-Asn-Gln-Gln-Glu-Lys-Asn-Glu-Gln-Glu-Leu-Leu-Glu-Leu-Asp-Lys-Trp-Ala-Ser-Leu-Trp-Asn-Trp-Phe-NH2
Cas-Nr. : 159519-65-0
Molekulare Formel : C204H301N51O64
Molekulargewicht : 4492
Reinheit (HPLC) : 98.0%min.
Aussehen : White to off-white amorphous solid
Einzelne Verunreinigung (HPLC) : 0.5%max
Aminosäurezusammensetzung : ±10% of theoretical
Peptidgehalt (N%) : ≥80,0 %
Wassergehalt (Karl Fischer) : ≤8,0 %
TrifluoroAcetate Content(HPIC) : ≤12,0 %
MS (ESI) : Consistent
Massenbilanz : 95.0~105,0 %
Grad : Pharmazeutische Qualität
Lagerung: Closed, below 2 ~ 8℃ preservation
Verwendung : Treatment option for patients suffering from HIV/AIDS.
Enfuvirtide is an antiretroviral drug used in combination therapy for the treatment of HIV-1/AIDS. It binds to the first heptad-repeat (HR1) in the gp41 subunit of the viral envelope glycoprotein and prevents the conformational changes required for the fusion of viral and cellular membranes. It works by disrupting the HIV-1 molecular machinery at the final stage of fusion with the target cell, preventing uninfected cells from becoming infected.
Enfuvirtid (GASTHOF) is an HIV fusion inhibitor, the first of a novel class of antiretroviral drugs used in combination therapy for the treatment of HIV-1 infection. It is marketed under the trade name Fuzeon (Roche).
